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Tumor necrosis factor (TNF)-related apoptosis-inducing ligand
(TRAIL) is a cytokine with potential therapeutic value against
cancers because of its selective cytotoxicity to many transformed,
but not normal, cells. The ‘‘decoy receptors’’ TRAIL-R3 (TR3) and
TRAIL-R4 (TR4) were believed to negatively regulate TRAIL-induced
cytotoxicity by competing for ligand binding with TRAIL-R1 (TR1)
and TRAIL-R2 (TR2). Here, we show that inhibition of TRAIL-
induced apoptosis by TR4 critically depends on its association with
TR2 via the NH2-terminal preligand assembly domain overlapping
the first partial cysteine-rich domain of both receptors. By contrast,
ligand binding by TR4 is dispensable for its apoptosis inhibitory
function, thereby excluding the possibility that TR4 was a ‘‘decoy’’
to inhibit apoptosis by binding up TRAIL. In primary CD8 T cells,
which express only TR2 and TR4 and are resistant to TRAIL-induced
apoptosis, stimulation with phorbol myristate acetate abrogated
the ligand-independent interaction between TR2 and TR4 and
enhanced their sensitivity to TRAIL-induced apoptosis. Hence,
whereas most TNF receptors normally form only homotrimeric
complexes, the preligand assembly domains in TR2 and TR4 permit
mixed complex formation as a means to regulate apoptosis induc-
tion. We propose that TR4 is a ‘‘regulatory’’ rather than ‘‘decoy’’
receptor that inhibits apoptosis signaling by TRAIL through this
previously uncharacterized ligand-independent mechanism.
decoy receptors
The regulation of cell death by members of the TNF familyplays a critical role in immune function and homeostasis (1).
TRAIL is a TNF-like cytokine that selectively induces apoptosis
in many tumor cells, but not in normal cells. Administration of
recombinant TRAIL or antibodies against TR2 in several ex-
perimental tumor models exhibited potent antitumor activity
with minimal hepatic toxicity (2–6). Moreover, recombinant
TRAIL or agonist TRAIL receptor antibody often synergizes
with chemotherapy or radiation to induce tumor-cell apoptosis
(7–10). This unique property of TRAIL has prompted many to
vaunt it as a potential therapeutic agent against malignant
diseases. Despite its potency against tumor cells, the physiolog-
ical function of TRAIL is largely unknown, although some
reports have implicated TRAIL to be involved in tumor sur-
veillance (11), target cell killing by various immune effector cells
(12, 13), and the regulation of innate immune responses (14).
TRAIL binds to five distinct TNF receptor (TNFR)-like
receptors, TR1 (TRAIL-R1DR4), TR2 (TRAIL-R2DR5
KillerTrick), TR3 (TRAIL-R3DcR1LITTRID), TR4
(TRAIL-R4DcR2TRUNDD), and the soluble receptor os-
teoprotegerin (OPG). OPG is a soluble receptor that also binds
another TNF-like cytokine called TRANCERANK-L and may
have a more prominent role in bone and myeloid cell develop-
ment than in regulating TRAIL-induced apoptosis. The four
membrane-anchored TRAIL receptors contain two complete
cysteine-rich domains (CRDs) for ligand binding that are pre-
ceded at the NH2 termini by a highly conserved partial CRDwith
unknown function (15, 16). TR1 and TR2 signal for apoptosis
through their cytoplasmic death domains (DDs). Similar to
FasCD95APO-1, stimulation of TR1 or TR2 results in the
recruitment of FADD and subsequently the initiator caspases
caspase-8 and caspase-10 (17). The recruited caspase-8 and
caspase-10 undergo autocatalytic cleavage and activation to
trigger the caspase cascade that ultimately leads to the apoptotic
death of the cell.
Unlike TR1 and TR2, neither TR3 nor TR4 contain intact
cytoplasmic DDs that signal for apoptosis. TR4 possesses a
partially truncated DD, whereas TR3 is anchored on the mem-
brane via glycosyl-phosphatidylinositol (GPI) linkage. Because
they can bind TRAIL but do not signal for apoptosis, TR3 and
TR4 have been proposed to serve as ‘‘decoys’’ that inhibit
apoptosis by sequestering TRAIL from the death-inducing
TRAIL receptors. Alternatively, the decoy receptors may inhibit
apoptosis by complexing with TR1 andor TR2 upon binding to
the trimeric ligand (18). Both of these ligand-dependent models
of inhibition of apoptosis by the decoy receptors require the
decoy receptors to bind TRAIL with relatively high affinities.
Moreover, they predict that high expression of the decoy recep-
tors will correlate with resistance to TRAIL-induced apoptosis.
Here, we report that inhibition of apoptosis by the decoy
receptor TR4 does not depend on ligand binding of the receptor.
Rather, inhibition of apoptosis critically depends on the forma-
tion of ligand-independent complexes between TR2 and TR4.
We found that the NH2 termini overlapping the first partial CRD
of TR2 and TR4, termed the preligand assembly domains
(PLADs), are essential for the formation of this ligand-
independent, death-inhibitory complex. The formation of this
death-inhibitory complex regulates sensitivity of primary human
CD8 T cells to TRAIL-induced apoptosis. Thus, PLAD-
mediated preligand receptor assembly is a previously uncharac-
terized mechanism by which TR4 regulates cellular sensitivity to
TRAIL-induced apoptosis.
Materials and Methods
Reagents.CD8 T cells, Jurkat cells, and BW5147 thymoma were
cultured in RPMI medium 1640. 293T cells were cultured in
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DMEM. All media were supplemented with 10% FCS, 100
unitsml penicillin, 100 gml streptomycin, 30 gml L-
glutamine, and 60 M 2-mercaptoethanol. Recombinant
TRAIL, antibodies against TRAIL receptors, and TRAIL re-
ceptor fusion proteins were obtained from R & D Systems and
Axxora Biochemicals.
TRAIL-Induced Cell Death in CD8 T Cells.CD8T cells were purified
from peripheral blood mononuclear cells by using the CD8 T cell
purification system (R & D Systems). FACS staining of TRAIL
receptor expression was performed by using specific antibodies
from Axxora Biochemicals. Cell death was induced with recom-
binant TRAIL upon treatment with 20 ngml phorbol myristate
acetate (PMA) for 30–240 min. Immunoprecipitation (IP) in
CD8 T cells were performed by using an antibody specific for
TR2 (R & D Systems). Western blots were performed by using
TR2 and TR4 antibodies. Small interference RNA was intro-
duced into primary CD8 T cells by using the Amaxa nucleo-
fection method. RNA interference (RNAi) sequences against
TR4 were: si506, r(GGAAGCUUCCAGGAUAAAA)dTdT;
and si1142, r(GGACAUGCAAAGGAAACAA)dTdT. Trans-
fection efficiency was typically 90% as determined by trans-
fection with a FITC-conjugated oligonucleotide duplex. Maxi-
mal silencing of TRAIL-R4 expression was normally achieved 4
days posttransfection.
293T Coimmunoprecipitation. 293T cells were transfected by using
FuGENE 6 (Roche). Twenty-four to 48 h posttransfection, cells
were harvested and lysed in IP buffer (150 mM NaCl20 mM
TrisCl, pH 7.51% Nonidet P-40) supplemented with Complete
protease inhibitors (Roche). After the lysates were cleared by
centrifugation, IP was performed by using monoclonal antibod-
ies against GFP (Roche), which also reacts with yellow fluores-
cent protein (YFP), for 2 h at 4°C with protein G coupled to
agarose beads. The beads were washed twice with IP buffer,
twice with IP buffer supplemented with 500 mMNaCl, and once
with IP buffer. Immunoprecipitates and whole-cell lysates were
resolved on 10% BisTris NuPAGE gels (Invitrogen).
TRAIL-Binding Assay. Murine BW5147 thymoma was transfected
with the respective TRAIL receptor expression plasmids encod-
ing TRAIL receptor fusions to the YFP by electroporation.
Twenty-four hours later, cells were stained with recombinant
FLAG-tagged TRAIL, followed by anti-FLAG tag antibody
(M2, Sigma) and goat anti-mouse IgG antibody conjugated to
phycoerythrin.
Functional Dominant Interference Assay. Jurkat cells were trans-
fected by electroporation with the BTX Electro Cell Manipu-
lator 600 (Genetronics). Transfected cells were treated with
TRAIL for 6 h at 37°C. In some experiments, TR fusion proteins
were added to the cells 15 min before stimulation with TRAIL.
Apoptosis of the transfected cells was analyzed by using phyco-
erythrin-conjugated Annexin V (BD Pharmingen) and YFP
fluorescence. The percentage of apoptotic cells in the trans-
fected population was determined by the percentage of YFP-
positive cells that also exhibited positive Annexin V staining.
Percentage of cell loss was determined as described in ref. 19.
Results
Successful expansion of memory CD8 T cells during recall
responses requires CD4T cell help and priming when the CD8
T cells are challenged during the primary response. The lack of
CD4 T cell help during primary antigenic challenge led to
abortive memory CD8 T cell expansion during recall response
due to TRAIL-induced apoptosis (20). This sensitization to
TRAIL-induced cell death could be attributed to the partial
activation signals the cells received during the initial antigen
priming stage in the absence of CD4 T cell help. We sought to
understand the mechanism that underlies the sensitization of
human primary CD8 T cells to TRAIL-induced apoptosis by
using PMA to mimic partial activation of CD8 T cells. We
found that human peripheral CD8 T cells or human CD8 T
cell clones that recognize the influenza M1 peptide were nor-
mally resistant to TRAIL-induced apoptosis. However, pretreat-
ment with PMA for as little as 30 min sensitized the cells to
TRAIL-induced apoptosis (Fig. 1A). Because CD8 T cells
express predominantly TR2 and TR4 on the cell surface (Fig.
1B), we speculated that the PMA-induced sensitization to
TRAIL-induced apoptosis might be caused by changes in cell-
surface expression of the inhibitory receptor TR4. Such a
scenario would be consistent with the previously reported se-
questration of decoy TRAIL receptors in an intracellular com-
partment as a means to modulate TRAIL responses (21).
Indeed, PMA stimulation did modestly reduce TR4 expression
on CD8 T cells (Fig. 1C, mean fluorescence intensity from 146
to 110). The expression of TR2 was also reduced slightly in
response to PMA (Fig. 1C, mean fluorescence intensity from
5.99 to 3.82). Hence, changes in cell-surface expression of TR2
and TR4 may account for the sensitization of CD8 T cells to
TRAIL-induced apoptosis.
Fig. 1. Protection against TRAIL-induced apoptosis in CD8 T cells requires
TR4. (A) PMA- or DMSO-treated CD8 T cells were stimulated with recombi-
nant TRAIL for 4 h before cell death determination by Annexin V staining. (B)
Peripheral blood mononuclear cells were stained with antibodies specific for
CD8 and TRAIL receptors as indicated. TRAIL receptor expression in CD8 T
cells was analyzed by histogram analysis. The shaded curves and the solid lines
represent staining with a control IgG and TRAIL receptor antibodies, respec-
tively. (C) PMA stimulation led to decreased surface expression of TR4. The thin
lines and the heavy lines represent DMSO- and PMA-treated cells, respectively.
(D) CD8 T cells were transfected with control RNAi or TR4-specific RNAi and
analyzed for cell-surface expression of TR2 or TR4. The shaded curves repre-
sent staining with control IgG. (E) CD8 T cells transfected with control RNAi
or TR4-specific RNAi (si506 and si1142) were treated with TRAIL, TNF, or FasL
as indicated and analyzed for cell death by flow cytometry. (F) TR2 was
immunoprecipitated from untreated or PMA-stimulated CD8 T cells. The
presence of TR4 and the two isoforms of TR2 (TR2L and TR2s) in the immune
complex (IP) and whole-cell extract (WCE) was detected by Western blot (WB)
as indicated. Results are representative of at least three experiments.
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Although PMA treatment sensitized cells to TRAIL-induced
apoptosis with a concomitant reduction in TR4 surface expres-
sion, it is possible that PMAmight trigger other molecular events
that contribute to the enhanced sensitivity to TRAIL. However,
we found no change in the expression of FADD, caspase-8, and
cFLIPL in the PMA-treated cells (data not shown). To determine
whether TR4 expression alone was sufficient to confer protec-
tion against TRAIL in CD8 T cells, we transiently knocked
down TR4 expression using RNAi. We found that RNAi against
TR4 specifically reduced expression of TR4, but not TR2
expression, in CD8 T cells (Fig. 1D). Moreover, RNAi-
mediated silencing of TR4 resulted in an enhanced sensitivity of
CD8 T cells to TRAIL-induced apoptosis (Fig. 1E). The effect
of the TR4 RNAi was specific to TRAIL because CD8 T cells
were not sensitized to TNF-induced apoptosis (Fig. 1E). More-
over, RNAi against TR4 did not affect Fas ligand-induced
apoptosis in CD8 T cells (Fig. 1E). Hence, TR4 plays a critical
role in the protection of CD8 T cells against TRAIL-induced
apoptosis.
Ligand-independent formation of receptor complexes plays a
crucial role in the function and signaling of TNF and Fas
receptors (22, 23). Although TNF and Fas receptors appear to
form only homotypic receptor complexes via the extracellular
PLAD, we hypothesized that the TRAIL receptors might form
mixed receptor complexes because of the high degree of homol-
ogy in their extracellular CRDs. Indeed, we found that TR2 and
TR4 associated with each other in CD8 T cells (Fig. 1F).
Strikingly, treatment with PMA abolished this interaction (Fig.
1F). Because these interactions occurred in the absence of
exogenously added TRAIL, our results strongly suggest that TR4
may inhibit apoptosis by complexing with TR2 before binding
exogenous TRAIL.
The inhibitory receptors TR3 and TR4 were thought to
protect cells against TRAIL-induced apoptosis by competing
with the death-inducing receptors for ligand binding. Alterna-
tively, the trimeric ligand TRAIL may drive the formation of an
abortive receptor complex containing TR1 or TR2 and the decoy
receptors (18). However, our data in CD8 T cells implied that
sensitivity to TRAIL might be regulated through ligand-
independent TR2–TR4 interaction. We therefore sought to
determine the precise role of ligand binding by TR4 in the
protection against TRAIL-induced cell death. We reasoned that
any ligand-dependent mechanisms of inhibition by TR3 or TR4
would require them to bind TRAIL with relatively high affini-
ties. Thus, we first evaluated the ligand-binding affinities of the
different TRAIL receptors using a cellular assay. Jurkat cells
express only TR2 and are highly sensitive to TRAIL-induced
apoptosis (24). We therefore compared the efficacy of soluble
TR-Fc fusion proteins [extracellular domain (ECD) of TR fused
to the constant region of Ig] to inhibit TRAIL-induced apoptosis
in Jurkat T cells as an indirect measurement of the ligand-
binding affinity of TRAIL receptors. We found that the half
maximal inhibitory dose (ID50) for TR3-Fc and TR4-Fc were 10-
to 100-fold greater than that of TR1-Fc and TR2-Fc (Fig. 2A),
indicating that TR3 and TR4 bind TRAIL with lower affinities
than TR1 and TR2. The weak inhibition by TR3-Fc and TR4-Fc
was not due to differences in protein stability or misfolding (Fig.
7, which is published as supporting information on the PNAS
web site). Our results are therefore consistent with that of
Truneh et al. (25), who showed that TR3 (Kd  200 nM) and
OPG (Kd  400 nM) bind TRAIL with much lower affinities
than that of TR1 (Kd  70 nM) and TR2 (Kd  2 nM). Hence,
TR3 and TR4 bind TRAIL with far lower affinities than TR1
and TR2, which does not support the model that they are
effective decoys for TRAIL.
Although soluble TR4-Fc did not bind TRAIL with high
affinity, transfection of full-length TR4 or TR4 with a cytoplas-
mic domain (CD) substitution with the YFP conferred strong
protection against TRAIL-induced apoptosis in Jurkat cells
(Fig. 2B and data not shown). The inhibition conferred by TR4
was as strong as that conferred by a similarly built dominant
negative TR2 and stronger than that of a dominant negative TR1
mutant (Fig. 2B). By contrast, a dominant negative version of
Fas did not interfere with TRAIL-induced apoptosis, although
it potently suppressed Fas-induced apoptosis. None of the
dominant negative TRAIL receptors had any effects on Fas-
induced apoptosis, indicating that the inhibitory effect was
specific against TRAIL (Fig. 2B). Flow cytometric measurement
of YFP fluorescence also revealed comparable expression be-
tween the different transfected samples (Fig. 8, which is pub-
lished as supporting information on the PNAS web site). Sur-
prisingly, transient or stable transfection of TR3 did not protect
against TRAIL-induced death in Jurkat cells (Fig. 2C and data
not shown). Collectively, these data indicate that TR4 could
potently interfere with TR2-mediated apoptosis, but ligand-
dependent mechanisms are unlikely to account for its inhibitory
effect.
Because ligand-independent receptor complex formation is
crucial for the function and signaling of TNF and Fas receptors
(22, 23, 26), we postulated that it might similarly control
apoptosis induction of TRAIL. Specifically, we reasoned that the
highly conserved extracellular CRDs between TR2 and TR4
might permit ligand-independent formation of mixed, abortive
receptor complexes. Such an event would produce heterotri-
meric complexes between TR2 and TR4 that would lack three
functional intracytoplasmic DDs and therefore would interfere
with apoptosis induction (27). We tested this proposition by
examining the interaction between different TRAIL receptors
lacking the cytoplasmic DDs. Because previous work indicates
that ligand-independent interactions occur in the ECD of the
Fig. 2. The decoy receptor TR4 is a low-affinity receptor for TRAIL but effectively inhibits apoptosis signaling by TR2 in Jurkat cells. (A) Jurkat 4E3 cells were
treated with TRAIL in the presence of the indicated amount of soluble TRAIL receptor Fc fusion proteins. Cell death was determined by flow cytometry. (B) The
indicated plasmids were transfected into Jurkat 4E3 cells and stimulated with the indicated doses of TRAIL or anti-Fas antibody. Apoptosis was monitored by
Annexin V staining. (C) Jurkat 4E3 cells were transfected with the indicated plasmids, stimulated with TRAIL, and analyzed for cell death. Results are
representative of three independent experiments.
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TNF and Fas receptors and that the cytoplasmic DDs have a
strong tendency to aggregate with one another (27), we removed
the cytoplasmic DDs from the TRAIL receptors before testing
them for ligand-independent associations. We found that the
ECDs of TR4 and TR2 interacted strongly with each other (Fig.
3 A and B, lanes 4 and 5, respectively). Remarkably, the
interaction between TR2 and TR4 appeared to be stronger than
that for homo-specific interaction [Fig. 3 A (compare lanes 4 and
6) and B (compare lanes 3 and 5)]. In addition, we also observed
mixed receptor interactions between the ECDs of TR1 and TR4
(Fig. 3A, lane 3), and TR1 and TR2 (Fig. 3 B and C, lanes 2 and
3, respectively), although the interaction between TR4 and TR1
seemed to be much weaker than that between TR2 and TR4.
Similar experiments with TR1 ECD as bait confirmed our
previous observation that TR1 can form strong homotypic
complexes with itself (Fig. 3C, lane 2) (22). Surprisingly, we did
not observe any interactions between TR3 and other TRAIL
receptors (Fig. 3 A–C, lanes 5, 4, and 4, respectively). Control
experiments with TNFR-2 p80 as bait revealed interaction with
the ECD of p80 but not with any other TRAIL receptor ECDs,
demonstrating the specificity of interactions among the TRAIL
receptors (Fig. 3D, lane 5).
The interaction between the ECD of TR2 and TR4 was
confirmed by FRET analysis with cyan fluorescent protein
(CFP)- and YFP-tagged receptors. An increase in FRET signal
was observed in cells cotransfected with TR2-CFPTR2-YFP,
TR4-CFPTR4-YFP, and TR2-CFPTR4-YFP receptor pairs
(Fig. 4 A–C, bold lines) compared with the noninteracting
receptor pairs TR2-CFPFas-YFP (Fig. 4A–C, thin lines). These
interactions did not require an intact ligand-binding site, because
the non-ligand-binding mutant TR4(R101A)-YFP could still
interact with wild-type TR2-CFP and TR4-CFP (Fig. 4D and
data not shown). Hence, the ECDs of TR2 and TR4 interact with
each other strongly in the absence of ligand.
We next sought to further delineate the domain within the
ECDs of TR2 and TR4 that mediate this ligand-independent
interaction. TR2 binds TRAIL through two patches of residues
within the two complete CRDs of the receptor while the
NH2-terminal partial CRD contributes little to ligand binding
(Fig. 5A, CRD2 and CRD3) (15, 16, 28). Because the PLADs in
TNFR-1, TNFR-2, and Fas are located within the membrane-
distal first CRD and are physically distinct from the ligand-
binding domain (22, 23), we hypothesized that the PLADs
located within the NH2-terminal partial CRD of TR2 and TR4
mediate formation of ligand-independent homo- and hetero-
typic receptor complexes (Fig. 5A). Indeed, deletion of the
NH2-terminal partial CRD in TR4 [HA-TR4(42–184)], but not
the non-CRD sequences preceding it [HA-TR4(27–184)], abol-
ished the association of TR4 with the ECD of TR2 (Fig. 5B,
compare lanes 2–4). Analysis of the whole-cell extracts showed
that all proteins were expressed at similar levels. Similar dele-
tions in TR2 revealed that the partial CRD at the NH2 terminus
was required for the interaction with TR4 (Fig. 5C, compare
lanes 2–4). Again, the interaction measured in this assay is
specific, because the Fas receptor was not precipitated (Fig. 5B,
lane 5). Thus, PLADs exist for TR2 and TR4 within the partial
CRD at the NH2 termini of the receptors. This arrangement is
similar to the PLADs in TNFR-1, TNFR-2, and Fas (22, 23).
Our results thus far strongly implicate that ligand-independent
mechanisms are involved in the inhibition of apoptosis by TR4.
However, it is possible that both ligand-dependent and -inde-
pendent mechanisms contribute to the inhibition of apoptosis by
TR4. To more definitively evaluate the contributions of ligand
binding and PLAD-mediated association to the inhibitory effect
of TR4 on TRAIL-induced apoptosis, we tested the PLAD-
deleted and non-ligand-binding TR4 mutants for protection
against TRAIL-induced apoptosis in Jurkat cells. Strikingly,
deletion of the PLAD completely eliminated the protective
Fig. 3. The ECDs of TRAIL receptors mediate ligand-independent interactions. HEK 293T cells were transfected with the indicated plasmids. Cells were harvested
for IP 24 h later by using an antibody against GFP, which also reacts with YFP. Western blots (WB) were performed by using HRP-conjugated HA-specific antibody
to detect expression of the receptors in IPs and whole-cell extracts (WCE), respectively. Open arrowheads, baits; filled arrowhead, preys; open circles, nonspecific
signals produced by truncation of the bait YFP proteins. Results are representative of three experiments.
Fig. 4. Flow cytometric analysis of FRET revealed homotypic and heterotypic
interactions of TR2 and TR4. HEK 293T cells were transfected with the indi-
cated FRET pairs and analyzed for FRET by flow cytometry (heavy lines). The
thin normal lines represent baseline FRET signals between the noninteracting
receptor pairs TR2CD-CFP and FasCD-YFP. Results are representative of
three independent experiments.
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effect of TR4 [Fig. 6A, TR4(42–184)-YFP]. As expected, the
DD-deleted TR2 and TR4 conferred strong protection (95%)
against TRAIL-induced death but not Fas-induced death (Fig.
6A). Moreover, the removal of the NH2-terminal non-CRD
sequences that were not essential for PLAD-mediated associa-
tion did not perturb the protective effect of TR4 [Fig. 6A,
TR4(27–184)-YFP]. Similar deletion mutants of TR2 revealed
that the NH2-terminal partial CRD was also required for dom-
inant interference of apoptosis by a tailless TR2 (Fig. 9, which
is published as supporting information on the PNAS web site).
A tailless, dominant-interfering Fas receptor had no effect on
TRAIL killing but strongly suppressed death induced by an
anti-Fas agonistic antibody (Fig. 6A). Strikingly, we found that
deletion of the PLAD, but not the NH2-terminal non-PLAD
sequences, abolished TRAIL binding by TR4 (Fig. 6B c and d).
The loss of TRAIL binding is unlikely to be caused by misfolding
of the receptor because the PLAD-deleted TR4 was expressed
on the cell surface and could be recognized by antibody specific
for TR4 (Fig. 10, which is published as supporting information
on the PNAS web site). Hence, the PLAD in TR4 is crucial for
receptor association and efficient ligand binding, similar to
TNFR-1 and TNFR-2 (22).
Although our results indicate that PLAD-mediated, ligand-
independent interaction between TR2 and TR4 impairs receptor
signaling of cell death, it is possible that deletion of the PLAD
resulted in severe disruption of the ligand-binding domain and
rendered the truncated receptor nonfunctional. To conclusively
show that ligand was not required for PLAD-mediated inhibition
of TR2, we tested the non-ligand-binding TR4mutant R101A for
inhibition against TRAIL-induced apoptosis in Jurkat cells. The
R101A mutation abolished ligand binding but did not interfere
with PLAD-mediated receptor interaction [Figs. 4D and 6B
(compare a and b)]. Significantly, the R101A mutant strongly
protected Jurkat cells against TRAIL-induced apoptosis at a
level comparable to that conferred by wild-type TR4 ECD (Fig.
6A). Similarly, an analogous mutation in TR2 (M97A) that
abolished ligand binding had no effect on the ability of a tailless,
dominant interfering TR2 to inhibit apoptosis (Fig. 9). Taken
together, our data clearly demonstrate that TR4 associates with
TR2 via the PLAD and that this ligand-independent association
between the two receptors is critically important for the inhib-
itory effect of TR4 on TR2-induced apoptosis.
Discussion
TR3 and TR4 were originally proposed to regulate TRAIL-
induced cytotoxicity through ligand competition or ligand-driven
formation of mixed trimer complexes with TR1 or TR2 (18). We
demonstrated here that TR4 inhibits TR2-mediated cytotoxicity
through ligand-independent association with TR2 via the PLAD.
Contrary to previous reports, we found no evidence that TR4
acts as a ‘‘decoy’’ that competes for ligand binding. In fact, our
evidence rules out that possibility. Because our data conclusively
overrule the ‘‘decoy’’ model for TR4 inhibition of TRAIL
signaling, we propose the term ‘‘regulatory receptor’’ for TR4.
Formation of TR2–TR4 heterotrimeric complexes explains how
the low-affinity receptor TR4 could effectively inhibit apoptosis
signaling by the high-affinity receptor TR2. In this case, as in the
other dominant interfering TNFR superfamily receptors, a
deficiency of the DD potently reduces the transmission of the
death signal (23, 27). Evidently, three intact DDs must be
present for signaling to occur normally. The PLADs in both
receptors allow both homotypic as well as heterotypic associa-
tions, unlike the homo-specific PLADs found in TNFR-1,
TNFR-2, and Fas. This property is likely attributable to the
strong sequence conservation within the PLADs of the TRAIL
receptors. It is noteworthy that the other decoy receptor TR3 did
not protect against TRAIL-induced apoptosis in Jurkat cells or
interact with other TRAIL receptor ECDs. It is possible that
TR3 may only interact with other TRAIL receptors in a complex
containing three distinct receptors. Further experiments will be
Fig. 6. Ligand-independent inhibition of TR2-induced apoptosis by TR4
requires an intact PLAD domain but not the ligand-binding domain. (A) The
indicated YFP-tagged chimeric receptors were transfected into Jurkat 4E3
cells, stimulated with TRAIL or anti-Fas antibody, and analyzed for cell death
by flow cytometry. (B) The indicated TR4CD-YFP receptors were transfected
into murine BW5147 cells, and TRAIL binding was determined by flow cytom-
etry. The histograms show TRAIL binding by the control FasCD-YFP receptor
(thin lines) and the different TR4 receptors (solid lines). Results are represen-
tative of five experiments.
Fig. 5. The PLADs of TR2 and TR4 are located within the partial CRD at the
NH2 termini. (A) Schematic diagram of the domain structure of TR2 and TR4.
The numbers above the arrows represent the boundaries of the deletions and
the positions of the alanine substitutions in the ligand-binding pocket of TR2
and TR4. The indicated deletion mutants of TR4 (B) and TR2 (C) were tested for
association with the ECDs of TR2 or TR4 in 293T cells. Results are representative
of three experiments.
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needed to evaluate the mechanism by which TR3 regulates
TRAIL-induced apoptosis.
Many cytokine receptors signal as multisubunit entities. The
association of the , , and  subunits of the IL-2 receptor
increases the affinity of the receptor. Swapping the  subunit of
the IL-2 receptor with that from the IL-15 receptor changes the
ligand specificity of the receptor. By contrast, the TR2–TR4
hetero-complexes did not alter the ligand specificity of the
receptor. Rather, TR2–TR4 hetero-complexes dramatically af-
fect the biological outcome of TRAIL stimulation through
inhibition of apoptosis. Although the TR2–TR4 complexes are
deficient for apoptosis induction, it is unclear whether they are
also defective in NF-B or MAP kinase signaling. Nonetheless,
the PLAD-mediated mixed complexes have a dramatic regula-
tory effect on the cellular response to TRAIL.
Ligand-independent association between TR2 and TR4 may
explain the resistance of CD8 T cells and other untransformed
cells to TRAIL. The lack of CD4 T cell help during priming of
CD8 T cells causes TRAIL-induced apoptosis of these cells,
which limits the expansion of the memory CD8 T cells during
secondary recall responses (20). Using PMA as a mimic for
partial activation without CD4 T cell help, we found that
primary CD8 T cells were rendered sensitive to TRAIL-
induced apoptosis. Strikingly, this change in cellular sensitivity to
TRAIL accompanied the abolition of ligand-independent inter-
action between TR2 and TR4. The heightened response to
TRAIL in PMA-treated CD8 T cells does not involve changes
in expression of apoptosis inhibitors such as cFLIP (data not
shown). Rather, RNAi-mediated knock down of TR4 expression
was sufficient to sensitize cells to TRAIL. These data strongly
implicate that ligand-independent interaction between TR2 and
TR4 is a regulatory mechanism that controls cellular sensitivity
to TRAIL. Similar regulation on the assembly of ligand-
independent Fas complexes and sensitivity to Fas-induced apo-
ptosis in CD4T cells has recently been reported, suggesting that
ligand-independent receptor assembly is a general mechanism
that regulates cellular sensitivity to death receptor stimulation
(29). Finally, mutations in the PLAD or ligand-binding domain
of TRAIL receptors have been identified in certain lung cancers
(30, 31). These mutations may affect ligand-independent recep-
tor assembly and cellular responses to TRAIL-induced apopto-
sis. Modulation of ligand-independent interactions between
TRAIL signaling and regulatory receptors may be a useful
strategy in cancer therapies.
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